Circulating concentrations and genetic variability of the FGF21/β-Klotho axis are associated with common comorbidities of chronic kidney disease
Background Chronic kidney disease (CKD) is frequently complicated by diabetes, dyslipidemia, and cardiovascular disease, which are not fully explained by traditional risk factors. We investigated whether circulating levels and genetic variability within the FGF21– β -Klotho–FGFR1 axis are associated with these CKD comorbidities. Methods A total of 579 CKD patients (30.1% CKD1–2, 15.5% CKD3 and 54.4% CKD4–5) were studied and followed for a median (interquartile range, IQR) of 34.9 (41.3) months. FGF21 and β -Klotho concentrations were measured by immunoassays, and 64 genetic variants across FGF21 , KLB and FGFR1 were genotyped. Associations with comorbidities were assessed using multivariate regression and survival analyses. Receiver operating characteristic (ROC) curves were used to evaluate predictive models. Results FGF21 concentrations increased with CKD severity [median (IQR): 275 (352), 537 (644) and 736 (906) pg/mL for CKD1–2, CKD3 and CKD4–5; p < 0.0001]. Both FGF21 and β -Klotho levels were higher in diabetic patients [FGF21: 672 (929) vs. 424 (621) pg/mL, p < 0.05; β -Klotho: 1,185 (910) vs. 1,018 (766) pg/mL, p < 0.01], whereas FGF21 was also elevated in dyslipidemia [632 (803) vs. 404 (563) pg/mL, p < 0.05]. An association of β -Klotho levels with increased CV risk [HR = 2.15 (1.11–4.16), p = 0.024] was observed, but lost significance after multivariable adjustment. Several KLB variants were associated with diabetes and dyslipidemia, while two FGFR1 SNPs, rs2288696 [HR = 0.45 (0.24–0.85), p < 0.01] and rs17580578 [HR = 0.48 (0.22–1.0), p < 0.05], were associated with better CV event-free survival, although the association did not survive correction for multiple testing. Models incorporating biomarkers and genetic data significantly improved discrimination for diabetes (AUC: 76.1 vs. 71.9%, p = 0.003) and dyslipidemia (74.1 vs. 70.8, p = 0.007). Conclusions Circulating FGF21 and β -Klotho levels, as well as genetic variability within their signaling pathway, are associated with comorbidities in CKD. The FGF21– β -Klotho axis may provide clinically relevant information beyond traditional risk factors in the renal setting.
Authors
- Sonia Mota-Zamorano (ORCID: https://orcid.org/0000-0003-4165-9613)
- Guillermo Gervasini (ORCID: https://orcid.org/0000-0002-0524-9767)
- Laura González-Rodríguez (ORCID: https://orcid.org/0009-0009-1648-0946)
- Celia Chicharro
- Bárbara Cancho (ORCID: https://orcid.org/0000-0003-3356-4040)
- Raquel Gil-Lozano (ORCID: https://orcid.org/0009-0006-4011-7299)
- Virginia Díaz-Acevedo
- Fernando Bandrés
- Nicolás R. Robles
- Manuel Martí-Antonio
- Zoraida Verde
Institutions
- Universidad de Valladolid (ES)
- Universidad Complutense de Madrid (ES)
- Instituto de Investigación Biomédica de Lleida (ES)
- Universidad de Extremadura (ES)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3389/fmed.2026.1970216
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Junta de Extremadura
- Instituto de Salud Carlos III